Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
Provided By GlobeNewswire
Last update: Oct 24, 2024
– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC)
– First safety data presented from combination study of PRT3789 and docetaxel demonstrated an acceptable safety profile
Read more at globenewswire.comNASDAQ:PRLD (7/25/2025, 8:17:57 PM)
0.93
+0.02 (+1.97%)
Find more stocks in the Stock Screener
